RxDoctor Payments Data

Sara Defurio, NP

Family · Iowa City, IANPI 1205380524

Payments from drug & device makers

$1,176in general payments, 2019–2025

Across 16 payments — averaging $73.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$215
  • Novo Nordisk$164
  • Lilly USA, LLC$162
  • AbbVie$158
  • Otsuka America Pharmaceutical, Inc.$122
  • Amgen$109
  • plus $247 from 5 others

What the payments were for

  • Food & beverage$1,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,176 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$36,061
Medicare patients
125
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$68,192
EliquisApixaban21$25,443
MounjaroTirzepatide13$13,568
Novolog FlexpenInsulin Aspart18$2,821
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$2,679
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$2,546
Albuterol Sulfate HfaAlbuterol Sulfate66$1,795
Atorvastatin Calcium221$1,512
Gabapentin50$1,063
Ultra-Fine Short Pen NeedlePen Needle, Diabetic19$1,060
SynthroidLevothyroxine Sodium20$1,010
Levothyroxine Sodium120$946
Metoprolol Succinate78$935
Omeprazole54$829
Bupropion XlBupropion Hcl29$812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$164$68,19265 claims
Lilly USA, LLCMounjaro$162$13,56813 claims
AbbVieSynthroid$158$1,01020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →